Getting under the skin: The immunopathogenesis of streptococcus pyogenes deep tissue infections

Clinical Infectious Diseases

Volumn 51, Issue 1, 2010, Pages 58-65

  Johansson, Linda ^a   Thulin, Pontus ^a,b   Low, Donald E ^c,d   Norrby Teglund, Anna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c MOUNT SINAI HOSPITAL   (United States)

^d PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; CYSTEINE PROTEINASE; IMMUNOGLOBULIN; PENICILLIN G;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; DRUG EFFICACY; DRUG MEGADOSE; GROUP A STREPTOCOCCAL INFECTION; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOGENESIS; NECROTIZING FASCIITIS; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; SEROTYPE; TOXIC SHOCK SYNDROME;

ADJUVANTS, IMMUNOLOGIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SKIN; SKIN DISEASES, BACTERIAL; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 77953769215     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653116     Document Type: Review

References (71)

1. Low DE, Schwartz B, McGeer A. The reemergance of severe group A streptococcal disease: an evolutionary perspective. In: Scheid WM, Armstrong D, Hughes JM, eds. Emerging infections, vol 7. Washington, DC: ASM Press, 1998:93-123.
2. Stevens DL. The flesh-eating bacterium: what's next? J Infect Dis 1999; 179 (Suppl 2):S366-S374.
3. Davies DH, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996;335:547-554.
4. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997; 103:18-24. (Pubitemid 27314183)
5. Hollingshead SK, Arnold J, Readdy TL, Bessen DE. Molecular evolution of a multigene family in group A streptococci. Mol Biol Evol 1994; 11:208-219. (Pubitemid 24075746)
6. Kalia A, Spratt BG, Enright MC, Bessen DE. Influence of recombination and niche separation on the population genetic structure of the pathogen Streptococcus pyogenes. Infect Immun 2002;70:1971-1983. (Pubitemid 34242198)
7. Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. Genetic corrrelates of throat and skin isolates of group A streptococci. J Infect Dis 1996; 173:896-900.
8. Kotb M, Norrby-Teglund A, McGeer A, et al. Immunogenetic and molecular basis for the differences in outcomes of invasive group A streptococcal infections. Nat Med 2002;8:1398-1404. (Pubitemid 36019425)
9. Adams EM, Gudmunsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med 1985; 145:10201023.
10. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7. (Pubitemid 19170377)
11. Nuwayhid ZB, Aronoff DM, Mulla ZD. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann Epidemiol 2007; 17:878-881.
12. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J Infect Dis 2006;193:1685-1692.
13. Linder A, Johansson L, Thulin P, et al. Erysipelas caused by group A streptococcus activates the contact system and induces the release of heparin-binding protein. J Invest Dermatol 2010;130:1365-1372.
14. Thulin P, Johansson L, Low DE, et al. Viable group A streptococci in macrophages during acute son tissue infections. PLoS Med 2006; 3: 371-379.
15. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-290.
16. Bryant AE, Bayer CR, Chen. RY, Guth PH, Wallace RJ, Stevens DJ. Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: the role of streptolysin O-induced platelet/neutrophil complexes. J Infect Dis 2005; 192:1014-1022.
17. LaPenta D, Rubens C, Chi E, Cleary PP. Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad Sci USA 1994;91:12115-12119. (Pubitemid 24368615)
18. Rohde M, Muller E, Chhatwal GS, Talay SR. Host cell caveolae act as an entry-port for group A streptococci. Cell Microbiol 2003; 5:323-342. (Pubitemid 37009910)
19. Medina E, Goldmann O, Toppel AW, Chhatwal GS. Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion. J Infect Dis 2003; 187:597-603.
20. Staali L, Morgelin M., Bjorck L, Tapper H. Streptococcus pyogenes expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. Cell Microbiol 2003; 5:253-265.
21. Osterlund A, Engstrand L. An intracellular sanctuary for Streptococcus pyogenes in human tonsillar epithelium-studies of a symptomatic carriers and in vitro cultured biopsies. Acta Otolaryngol 1997; 117:883-888.
22. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 1997; 107:640-647.
23. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511.
24. Olsen RJ, Shelbourne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 2009; 11:1-12.
25. Johansson L, Thulin P, Sendi P, et al. Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun 2008; 76:3399-3404.
26. Aziz RK, Pabst MJ, Jeng A, et al. Invasive M1T1group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degaradation of mutliple virulence factors by SpeB. Mol Microbiol 2004;51:123-134.
27. Svensson MD, Scaramuzzino DA, Sjobring U, Olsen A, Frank C, Bessen DE. Role for a secreted cysteine proteinase in the establishment of host tissue tropism by group A streptococci. Mol Microbiol 2000; 38:242-253.
28. Kuo CF, Wu JJ, Lin KY, et al. Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infect Immun 1998;66:3931-3935. (Pubitemid 28347857)
29. Lukomski S, Montgomery CA, Rurangirwa J, et al. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect Immun 1999;67:1779-1788.
30. Beres SB, Richter EW, Nagiec MJ, et al. Molecular genetic anatomy of inter- and intraserotype variation in the human bacterial pathogen group A. Streptococcus. Proc Natl Acad Sci USA 2006; 103:7059-7064.
31. Olsen RJ, Sitkiewicz I, Ayeras AA, et al. Decreased necrotizing fasciitis capacity caused by a single nudeotide mutation that alters a multiple gene virulence axis. Proc Natl Acad Sci U S A 2010; 107:888-893.
32. Rasmussen M, Bjorck L. Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol Microbiol 2002;43:537-544.
33. Walker MJ, Hollands A, Sanderson-Smith ML, et al. DNase Sdal provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007;13:981-985. (Pubitemid 47222039)
34. Rasmussen M., Muller HP, Bjorck L. Protein GRAB of Streptococcus pyogenes regulates proteolysis at the bacterial surface by binding alpha2macroglobulin. J Biol Chem 1999;274:15336-15344.
35. Nyberg P, Rasmussen M, Björck L. a2-Macroglobulin-proteinase complexes protects Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J Biol Chem 2004;279:52820-52823.
36. Norrby-Teglund A, Chatellier S, Low DE, McGeer A, Green K, Kotb M. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 2000; 30:3247-3255.
37. Norrby-Teglund A, Thulin P, Gan BS, et al. Evidence for superantigen involvement, in severe group A streptococcal tissue infection. J Infect Dis 2001; 184:853-860. (Pubitemid 32881089)
38. Norrby-Teglund A, Pauksens K, Norgren M, Holm S. Correlation, between serum TNFa and IL6 levels and severity of group A streptococcal infections. Scand J Infect Dis 1995;27:125-130.
39. Sriskandan S, Moyes D, Lemm G, Cohen J. Lymphotoxin-a (TNF-b) during sepsis. Cytokine 1996;8:933-937.
40. Cywes C, Wessels MR. Group A Streptococcus tissue invasion by CD44mediated cell signalling. Nature 2001;414:648-652.
41. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278:672-675. (Pubitemid 27464963)
42. Leung DY, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T-cell expression of the skinselective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukine 12 production. J Exp Med 1995; 181:747-753.
43. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-1828.
44. Strickland I, Hauk PJ, Trumble AE, Picker LJ, Leung DY. Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis. J Invest Dermatol 1999;112:249-253. (Pubitemid 29061984)
45. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984; 310(26):1689-1693. (Pubitemid 14083438)
46. Edwards RJ, Taylor GW, Ferguson M, et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis 2005; 192:783-790.
47. Hidalgo-Grass C, Dan-Goor M, Maly A, et al. Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections. Lancet 2004;363:696-703. (Pubitemid 38296556)
48. Zinkernagel AS, Timmer AM, Pence MA, et al. The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe 2008;4(2):170-178.
49. Herwald H, Cramer H, Mörgelin M., et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004; 116:367-379. (Pubitemid 38366314)
50. Johansson L, Linnér A, Sundén-Cullberg J, et al. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. J Immunol 2009; 183:4047-4054.
51. Kahn F, Mörgelin M, Shannon O, et al. Antibodies against a surface protein of Streptococcus pyogenes promote a pathologic inflammatory response. PLoS Pathog 2008;4(9):e1000149.
52. Soehnlein O, Oehmcke S, Ma X, et al. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. Eur Respir J 2008;32:405-412.
53. Beisswenger C, Bals R. Functions as antimicrobial peptides in host defense and immunity. Curr Protein Pept Sci 2005; 6:255-264. (Pubitemid 40812749)
54. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414:454-457. (Pubitemid 34173727)
55. SchmidtchenA, Frick IM, Andersson E, TapperH, BjorckL. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 2002;46:157-168. (Pubitemid 35238020)
56. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Bjorck L. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 2003;278:16561-16566.
57. Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001; 117:91-97. (Pubitemid 32652444)
58. Gryllos I, Tran-Winkler HJ, Cheng MF, et al. Induction of group A Streptococcus virulence by a human antimicrobial peptide. Proc Natl Acad Sci USA 2008;105:16755-16760.
59. Basma H, Norrby-Teglund A, Guedez Y, et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 1999;67:1871-1877. (Pubitemid 29144409)
60. Mascini EM, Jansze M, Schellekens JF, et al. Invasive group A streptococcal disease in the Netherlands: evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis 2000; 181:631-638. (Pubitemid 30131832)
61. Norrby-Teglund A, Ihendyane N, Kansal R, et al. Relative neutralizing activity in polyspecifie IgM., IgA, and IgG preparations against group A streptococcal superantigens. Clin Infect Dis 2000;31:1175-1182.
62. Basma H, Norrby-Teglund A, McGeer A, et al. Opsonic antibodies to the surface M. protein, present in pooled normal immunoglobulins (IVIG), may contribute to its clinical efficacy in severe invasive group A. streptococcal infections. Infect Immun 1998;66:2279-2283. (Pubitemid 28194131)
63. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal superantigen neutralizing antibodies in normal polyspecific IgG (IVIG). Infect Immun 1996;64:5395-5398.
64. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996;156:3057-3064. (Pubitemid 126660657)
65. Skansen-Saphir U, Andersson J, Björk L, Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994; 24:916-922. (Pubitemid 24093788)
66. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997;100:151-157. (Pubitemid 27349853)
67. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104 (suppl 1):3-9.
68. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 2003; 35: 683-689.
69. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. Clin Infect Dis 1999;28:800-807.
70. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized double-blind placebo-controlled trial. Clin Infect Dis 2003; 37:333-340.
71. Norrby-Teglund A, Müller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using intravenous polyspecifie immunoglobulin and a conservative surgical approach. Scand J Infect Dis 2005;37:166-172.